BrainCool AB (publ) can announce that the first patient has been treated with RhinoChill® System and BrainCool™ System during a thrombectomy procedure in the COTTIS 2 study.
 
The COTTIS 2 (Combination of Targeted temperature management and Thrombectomy after acute Ischemic Stroke) clinical trial intends to measure the outcome in acute stroke patients with large vessel occlusion treated with the combination of hypothermia and thrombectomy.
 
On June 28th, 2024, BrainCool AB communicated in a press release that all the criteria had been fulfilled to enroll the first patient in the pivotal COTTIS 2 trial, which is equivalent to a phase 3 clinical trial. COTTIS 2 is a multicenter randomized clinical trial with a total of 400 patients. Professor Dr. Jürgen Bardutzky at the University Hospital of Freiburg is the principal investigator of COTTIS 2.
 
Please see the press release mentioned above for more details regarding COTTIS 2 and ischemic stroke.
 
https://www.braincool.se/press-releases

Contact
For more information
Jon Berg - CEO
+46 722 50 91 19
E-mail: jon.berg@braincool.se

About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.

Attachments
BrainCool AB (publ) – the first patient has been treated with RhinoChill® System in the pivotal COTTIS 2 study

© Modular Finance, source Nordic Press Releases